Cited 16 times in
Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김창수 | - |
dc.contributor.author | 김형수 | - |
dc.contributor.author | 정보영 | - |
dc.date.accessioned | 2019-07-23T06:56:09Z | - |
dc.date.available | 2019-07-23T06:56:09Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/170382 | - |
dc.description.abstract | Background and Objectives Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF. Methods We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation. Results Number of patients with CHA2DS2-VASc scores 0, 1 and ≥2 were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA2DS2-VASc scores ≥2, the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42% and 0.15%, and those of gastrointestinal bleeding were 0.32% and 0.15% in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of $20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of $17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of $3,735, resulting in an incremental cost-effectiveness ratio of $9,707 per QALY. Conclusions Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Korean Society of Circulation | - |
dc.relation.isPartOf | KOREAN CIRCULATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Preventive Medicine and Public Health (예방의학교실) | - |
dc.contributor.googleauthor | Hyunmee Kim | - |
dc.contributor.googleauthor | Hyeongsoo Kim | - |
dc.contributor.googleauthor | Seong-Kyung Cho | - |
dc.contributor.googleauthor | Jin-Bae Kim | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.contributor.googleauthor | Changsoo Kim | - |
dc.identifier.doi | 10.4070/kcj.2018.0220 | - |
dc.contributor.localId | A01042 | - |
dc.contributor.localId | A05740 | - |
dc.contributor.localId | A03609 | - |
dc.relation.journalcode | J01952 | - |
dc.identifier.eissn | 1738-5555 | - |
dc.subject.keyword | Atrial fibrillation | - |
dc.subject.keyword | Rivaroxaban | - |
dc.subject.keyword | Warfarin | - |
dc.subject.keyword | Cost effectiveness | - |
dc.contributor.alternativeName | Kim, Chang Soo | - |
dc.contributor.affiliatedAuthor | 김창수 | - |
dc.contributor.affiliatedAuthor | 김형수 | - |
dc.contributor.affiliatedAuthor | 정보영 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 252 | - |
dc.citation.endPage | 263 | - |
dc.identifier.bibliographicCitation | KOREAN CIRCULATION JOURNAL, Vol.49(3) : 252-263, 2019 | - |
dc.identifier.rimsid | 62582 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.